Decode Genetics and Pfizer are collaborating to discover sequence variants associated with clinical phenotypes of systemic lupus erythematosis, Decode said this week.
Over the next 18 months, the partners will jointly analyze the genomes of an undisclosed number of lupus patients, with the aim to find sequence variants that could help them understand existing drug targets and identify novel targets. Another goal is to develop tools for patient stratification and companion diagnostics.
The collaboration will make use of Decode's population genetics resources and analytical expertise, including next-gen sequencing, and Pfizer's ability to apply genomic analyses to drug discovery and development.
According to its website, Decode has collected genotypic and medical data from more than 140,000 volunteers in Iceland, or more than half the island's adult population.